You are here:

SIGs

Thur 8 May

0745 - 0845

1A  Epilepsy | 1C  Neuro Infection | 3A  Peripheral Nerve | 3B  TBI

Epilepsy

1A  Chair: Lina Nashef

Paul Cooper: Predicting risk of epilepsy per year post head injury: When would DVLA requirements be met and when can driving resume? A neurologist’s guide

Tony Marson: Factors predicting recurrence after anti-seizure medication withdrawal and likelihood of regaining control in the event of recurrence

William Stern: An update on studies on valproate and possible transgenerational effect in men – how to safely navigate the uncertainty

Dorothy Joe: Surgery for epilepsy for low grade lesions in neuro-oncology practice – A missed opportunity?

Neuro Infection

1C Clinical Challenges in the Investigation and Management of Encephalitis
1C  
Chair: Benedict Michael

Benedict Michael: Welcome and Introduction

Bhagteshwar Singh, Liverpool: Encephalitis in the returning traveller

Laura Benjamin, UCL: Encephalitis in the immuncompromised

Matt Jones, Manchester: Autoimmune encephalitis challenge

Peripheral Nerve

3A  Diabetic Neuropathies: Making it Painless 
Sponsored by Alnylam & Argenx – Teas/Coffee & pastries provided
Chair: Tim Lavin

Matthew Evans: Small Fibre Neuropathies

Arjuna Nagendran: An approach to conduction slowing in a diabetic: Could it be CIDP?

TBI

3B  Chairs: Peter Jenkins & Lucia Li

James Mitchell, Birmingham: Management of acute and prolonged post-concussion symptoms

Damian Jenkins, Oxford: Distinguishing trauma in traumatic brain injury: military case studies

Thomas Parker, Imperial: Brain health outcomes in retired professional rugby and football players (the Advanced Brain Health Clinic study)

Fri 9 May

0750 - 0850

1A  Cognitive | 1C  Autonomic | 3A  FND | 3B  Neuro-oncology

Cognitive

1A Oncological interventions for Glioma – Time to involve the neurologist?
1A Chair: Akram Hosseini

Mark Ellul: Long-term cognitive outcomes after autoimmune encephalitis

Benedict Michael: Longer-term cognitive consequences after COVID infection

Ava Easton: Cognitive challenges following autoimmune encephalitis

Autonomic

1C Biomarkers of Early Autonomic Disease
1A Chair: Gordon Ingle

Gordon Ingle, Valeria Iodice, Patricia McNamara and Giacomo Chiaro present an overview of existing biomarkers and how these can be used in early assessment of autonomic failure. The session will involve interactive discussion, giving examples and case studies. The speakers will update on progress to make Droxidopa available for neurological use via NHS England and share plans for a UK wide Autonomic MDT and a UK Autonomic Society to work alongside the Special Interest Group.

FND

3A What should an FND service look like?
1A Chair: Marianne Novak

Marianne Novak, Beth Mallam & Christine Burness

The structure of FND services varies across existing UK services, while many regions do not have an FND service at all. There is significant inequality of access to specialist healthcare for people with FND as a result. We would like to (a) present three UK FND services as examples of different models, and (b) discuss what makes a successful FND service, what challenges are faced in developing and sustaining these services, and what are the ways in which we can support each other in developing new services.


Neuro-oncology

3B Oncological interventions for Glioma – Time to involve the neurologist? 
1A Chair: Shanika Samarasekera

Satheesh Ramalingam, Birmingham: Is it a tumour? Identifying radiologically- challenging lesions

Catherine McBain, Manchester: The potential benefits and side effects of Vorasidenib for the treatment of Low Grade Glioma- local experience

Sara Meade, Birmingham: Indigo and beyond: An overview of the Vorasidenib trials and their implications for service delivery in neuro-oncology

Round table discussion: Should neurologists deliver oncological therapies – Is it time for a reconfiguration of services?